Fujian Haixi Pharmaceuticals (HKG:2637) said the U.S. Food and Drug Administration approved its investigational new drug application for HX9428, an experimental treatment for neovascular age-related macular degeneration (nAMD), allowing a Phase II clinical trial to proceed in the U.S.
The company also started a second Phase II trial in China to evaluate the treatment against Aflibercept, a standard therapy for the eye disease.
The study is expected to enroll 60 patients.